AmoyDx® Essential NGS Panel
White Paper
1. Comparative Analysis of Essential NGS Panel Data on MGI DNBSEQ-G50 and NextSeq 550
The study confirms that the AmoyDx® Essential NGS Panel performs exceptionally well on both MGI G50 and NextSeq 550 platforms. The MGI G50 demonstrated superior sequencing quality and depth while maintaining comparable accuracy, mutation frequency detection, and detection performance. These findings validate MGI G50 as a robust and reliable platform for detecting the target region of the 10 key solid tumor genes from the panel in both clinical and research applications.Mutations( Hover over each mutational type to highlight genes covered )
EGFR
ALK
ROS1
RET
KRAS
NRAS
PIK3CA
BRAF
HER2
MET
Fast turnaround time within
1 week
Automatic and secure data analysis
Target 10 driver genes for NSCLC/CRC
Detection of SNV, InDel, fusion, CNV
Specifications
cfDNA: ≥10 ng (optimal 30 ng)
Publications
1. Yang, James Chih-Hsin et al. Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial. Journal of Thoracic Oncology, Volume 18, Issue 12, 1743 - 1755.
2. Ren, W.; Zhu, Y.; Wang, Q.; Jin, H.; Guo, Y.; Lin, D. Deep Learning-Based Classification and Targeted Gene Alteration Prediction from Pleural Effusion Cell Block Whole-Slide Images. Cancers 2023, 15, 752.
3. Qiu, D., Xi, H., Wang, M. et al. The debatable role of immune checkpoint blockade therapy in lung adenocarcinoma-oriented liver metastatic malignant lesions. J Cancer Res Clin Oncol 149, 5791–5802 (2023).
4. Cai, Y., Liu, H., Chen, X., Yang, J., & Huang, B. (2023). P40 and TTF‑1 double‑expressing non‑small cell lung cancer with EML4‑ALK and PIK3CA gene mutations: A case report and review of the literature. Oncology Letters, 25, 59.
5. Takamori S, Seto T, Yamaguchi M, Kinoshita F, Fujishita T, Ito K, Toyozawa R, Shoji F and Okamoto T (2022) Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation. Front. Oncol. 12:965741.
6. Ou, Sai-Hong Ignatius et al. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2). Journal of Thoracic Oncology, Volume 17, Issue 12, 1404 - 1414.
7. Ma Y, Li Q, Du Y, Chen W, Zhao G, Liu X, Li H, Liu J, Shen Z, Ma L, Zhou Y. Oncogenic Genetic Alterations in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China. Cancer Manag Res. 2020;12:10861-10874.
8. Wu, W., Huang, Y., Guo, J., Xie, X., Li, H., Cao, Z., Wei, H. and Wu, C. (2020), Detection and comparison of EGFR mutations from supernatants that contain cell-free DNA and cell pellets from FNA non–small cell lung cancer specimens. Cancer Cytopathology, 128: 545-552.
9. Wu, W., Cao, Z., Zhang, W. et al. Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients. Diagn Pathol 15, 9 (2020).
10. Xu H, Baidoo AA, Su S, Ye J, Chen C, Xie Y, Bertolaccini L, Ismail M, Ricciuti B, Ng CS, Flores RM, Li Y; written on behalf of AME Lung Cancer Collaborative Group. A comparison of EGFR mutation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients. Transl Lung Cancer Res 2019;8(2):135-143.
11. Xiuhuan Ji, Nanying Che, Rixu lin, Jianou Chen, Xiuling Wu. Efficient ten-gene analysis of NSCLC tissue samples by next-generation sequencing. Pathology - Research and Practice, Volume 215, Issue 5, 2019, Pages 1066-1070.